Patritumab Deruxtecan for the Treatment of Patients with Newly Diagnosed or Recurrent Brain Metastases

Inclusion Criteria

• Participants must have newly diagnosed or recurrent BrM, with one of the metastases being surgically resectable. Primary tumor histology must be one of the following solid tumor types: * Melanoma (cutaneous skin) * Stomach adenocarcinoma (intestinal subtype) * Breast invasive carcinoma ** ER+/PR+/HER2- ** HER2+ (any ER/PR status) ** Triple negative (ER-/PR-/HER2-) * Cancer of the head and neck (including but not limited to squamous cell carcinoma of the head and neck) * Bladder Urothelial carcinoma * Ovarian serous cystadenocarcinoma ** Serous subtype ** Mucinous subtype * Cholangiocarcinoma * Prostate adenocarcinoma * Lung carcinoma - non-small cell lung carcinoma (NSCLC)
• Participant must be asymptomatic or minimally/well-controlled symptomatic from BrM * Asymptomatic is defined as free of neurologic signs and symptoms related to metastatic brain lesions and not having required or received systemic corticosteroid therapy within 10 days prior to administration of patritumab deruxtecan * Minimally/well-controlled symptomatic is define as having neurologic signs and symptoms may be treated with a total daily dose of no more than 4 mg of dexamethasone (or equivalent) that is stable or tapering for 10 days prior to administration of patritumab deruxtecan. Participants with neurologic signs and symptoms who are not being treated with steroids or being controlled by a stable dose of ≤4 mg dexamethasone or equivalent steroids are eligible and should have no experience of seizure within 5 days prior to administration of patritumab deruxtecan ** NOTE: Subjects’ steroid doses will be tapered for the purposes of this study
• Participant must be eligible and willing to undergo resection of their tumor
• Participants must be willing and able to undergo placement and implantation of an Ommaya reservoir into the ventricle contralateral to the brain lesion at the time of surgical removal of the brain lesion
• Participant or partner(s) meets one of the following criteria: * If the participant is a person of childbearing potential, they must have a negative serum pregnancy test at screening and must be willing to use a highly effective birth control upon enrollment, during the treatment period, and for 7 months, following the last dose of study drug. An individual is considered of childbearing potential following menarche and until becoming postmenopausal (no menstrual period for a minimum of 12 months) unless permanently sterile (undergone a hysterectomy, bilateral salpingectomy or bilateral oophorectomy) with surgery at least 1 month before the first dose or confirmed by follicle stimulating hormone (FSH) test * Participants must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration * If the participant is capable of producing sperm, the participant must be surgically sterile or willing to use a highly effective birth control upon enrollment, during the treatment period, and for at least 4 months following the last dose of study drug * Participants must not freeze or donate sperm starting at screening and throughout the study period, and for at least 4 months after the final study drug administration
• Age ≥ 18 years of age at the time of entry into the study
• Karnofsky Performance Score (KPS) of 70 or higher
• Platelet count ≥100 000/mm^3 or ≥100 × 10^9/L (platelet transfusions are not allowed up to 14 days prior to cycle 1 day 1 to meet eligibility) (within 14 days prior to administration of patritumab deruxtecan)
• Hemoglobin (Hgb) ≥9.0 g/dL (transfusion and/or colony stimulating factor support is allowed) (within 14 days prior to administration of patritumab deruxtecan)
• Absolute neutrophil count (ANC) ≥1500/mm^3 or ≥1.5 × 10^9/L (within 14 days prior to administration of patritumab deruxtecan)
• Creatinine clearance (CrCl) ≥30 mL/min as calculated using the Cockcroft-Gault equation or measured CrCl (within 14 days prior to administration of patritumab deruxtecan)
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤3 × Upper Limit of Normal (ULN) (if liver metastases are present, ≤5 ×ULN) (within 14 days prior to administration of patritumab deruxtecan)
• Total bilirubin (TBL) ≤1.5 × ULN if no liver metastases (<3 × ULN in the presence of documented Gilbert’s Syndrome [unconjugated hyperbilirubinemia] or liver metastases) (within 14 days prior to administration of patritumab deruxtecan)
• Serum albumin ≥2.5 g/dL (within 14 days prior to administration of patritumab deruxtecan)
• Prothrombin time (PT) or PT-international normalized ration (INR) and activated partial thromboplastin time (aPTT)/partial thromboplastin time (PTT) ≤1.5 × (ULN), except for subjects receiving coumadin-derivative anticoagulants or other similar anticoagulant therapy, who must have PT-INR within therapeutic range as deemed appropriate by the investigator (within 14 days prior to administration of patritumab deruxtecan)
• A signed informed consent form (ICF) approved by the Institutional Review Board (IRB) will be required for patient enrollment into the study. Participants must be able to read and understand the informed consent document and must sign the informed consent indicating that they are aware of the investigational nature of this study
• Ability to undergo MRI

Exclusion Criteria

• Participants who are pregnant or breast-feeding or intend to become pregnant during the study
• Participants with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeons or their designate
• Participants with severe, active co-morbidity, defined as follow: * Participants with an active infection requiring intravenous treatment or having an unexplained febrile illness (Tmax > 99.5 degrees Fahrenheit [F]/37.5 degrees Celsius [C]) * Participants with known immunosuppressive disease or known human immunodeficiency virus (HIV) infection * Participants with unstable or severe intercurrent medical conditions such as severe heart disease (New York Heart Association Class 3 or 4)
• Participants with another malignancy within 1 year prior, except for adequately resected non-melanoma skin cancer, superficial bladder tumors (Ta, Tis, T1), adequately treated intraepithelial carcinoma of the cervix uteri, low risk non-metastatic prostate cancer (with Gleason score <7 and following local treatment or ongoing active surveillance), curatively treated in-situ disease, or other solid tumors curatively treated
• Participants with a known history of hypersensitivity to patritumab deruxtecan, or any components of patritumab deruxtecan
• Participants who were previously treated with patritumab deruxtecan
• Participants with active autoimmune disease requiring systemic immunomodulatory treatment within the past 3 months
• Participants with any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis), has current ILD, or is suspected to have such disease by imaging during screening
• Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g. pulmonary emboli within three months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, pleural effusion, etc.)
• Any autoimmune connective tissue or inflammatory disorders (e.g., Rheumatoid arthritis, Sjogren’s, sarcoidosis, etc.) where there is documented, or a suspicion of pulmonary involvement at the time of screening. Full details of the disorder should be recorded in the electronic case report form (eCRF) for patients who are included in the study
• Prior complete pneumonectomy
• Participant is receiving chronic systemic corticosteroids dosed at > 4 mg dexamethasone (Decadron) or equivalent anti-inflammatory activity or any form of immunosuppressive therapy within 1 week prior to cycle 1 day 1. Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study
• Evidence of any leptomeningeal disease
• Has clinically significant corneal disease
• Any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses, active infection, psychiatric illness/social situations, geographical factors, substance abuse, or other factors which in the investigator’s opinion makes it undesirable for the participant to participate in the study or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required for eligibility
• Inadequate washout period prior to cycle 1 day 1, defined as: * Whole brain radiation therapy <14 days or stereotactic brain radiation therapy <7 days * Any cytotoxic chemotherapy, investigational agents or other anticancer drug(s) from a previous cancer treatment regimen or clinical study <14 days or 5 half-lives, whichever is longer * Monoclonal antibodies other than immune checkpoint inhibitors, such as bevacizumab (anti-VEGF) and cetuximab (anti-EGFR) <28 days * Immune checkpoint inhibitor therapy < 21 days * Major surgery (excluding placement of vascular access) < 28 days * Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation < 28 days or palliative radiation therapy < 14 days * Chloroquine or hydroxychloroquine ≤ 14 days
• Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, grade ≤1 or baseline. Participants with chronic, stable grade 2 toxicities (defined as no worsening to > grade 2 for at least 3 months prior to randomization/cycle 1 day 1 and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, comprised of the following adverse events (AEs), are eligible to enroll: * Chemotherapy induced neuropathy * Fatigue * Residual toxicities from prior immunotherapy treatment: Grade 1 or Grade 2 endocrinopathies which may include: ** Hypothyroidism/hyperthyroidism ** Type I diabetes ** Hyperglycemia ** Adrenal insufficiency ** Adrenalitis ** Skin hypopigmentation (vitiligo)
• Uncontrolled or significant cardiovascular disease prior to cycle 1 day 1, including: * QT interval corrected by Fridericia's formula (QTcF) prolongation interval of >450 ms (average of triplicate determinations at screening) * Resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg * Myocardial infarction within 6 months * New York Heart Association Classes 3 to 4 congestive heart failure within 28 days * Uncontrolled angina pectoris within 6 months * Cardiac arrhythmia requiring antiarrhythmic treatment * Left ventricular ejection fraction (LVEF) <45%
• Active hepatitis B and/or hepatitis C infection, such as those with serologic evidence of viral infection within 28 days of cycle 1, day 1. NOTE: Participants will be tested for hepatitis B (HepB/C) during screening and at follow-up on this study, if there is a known history of either Hepatitis B or C. Participants will not be tested for HIV * Participants with past or resolved Hepatitis B virus (HBV) infection are eligible if: ** Hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive; OR ** HBsAg positive and HBV deoxyribonucleic acid (DNA) viral load is documented to be ≤ 2000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with normal transaminases (in the absence of liver metastasis); OR ** HBsAg positive and HBV DNA viral load is documented to be ≤ 2000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with liver metastasis and abnormal transaminases AST/ALT < 3 ULN * Participants with a history of Hepatitis C virus (HCV) infection will be eligible for enrollment only if the viral load according to local standards of detection, is documented to be below the level of detection in the absence of anti-viral therapy during the previous 12 weeks (i.e., sustained viral response according to the local product label but no less than 12 weeks, whichever is longer)
• Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator’s judgment, could affect the safety of the subject; alter the absorption, distribution, metabolism or excretion of the study drug; or confound the assessment of study results
• Has known hypersensitivity to either the drug substance or inactive ingredients in the drug product